| Market Capitalization (Millions $) |
2 |
| Shares
Outstanding (Millions) |
3 |
| Employees |
11 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-7 |
| Cash Flow (TTM) (Millions $) |
1 |
| Capital Exp. (TTM) (Millions $) |
0 |
Avenue Therapeutics Inc
Avenue Therapeutics Inc. is a pharmaceutical company focused on the development and commercialization of an intravenous (IV) form of an opioid pain medication called Tramadol. Tramadol is commonly used to manage moderate to severe pain, and Avenue Therapeutics aims to provide a potentially safer and more effective alternative to existing IV pain medications. The company is dedicated to improving patient care and addressing the opioid crisis by offering a non-addictive solution for acute pain relief. Avenue Therapeutics is based in New York City, and it is a subsidiary of InvaGen Pharmaceuticals, a global pharmaceutical company.
Company Address: 1111 Kane Concourse, Suite 301 Bay Harbor Islands 33154 FL
Company Phone Number: 652?4500 Stock Exchange / Ticker: ATXI
|
0.000%
5.43%